Federated Hermes Inc. Has $45,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Federated Hermes Inc. reduced its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 99.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,845 shares of the company's stock after selling 2,736,920 shares during the quarter. Federated Hermes Inc.'s holdings in Intellia Therapeutics were worth $45,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Whipplewood Advisors LLC bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics in the 4th quarter valued at $43,000. Jones Financial Companies Lllp lifted its stake in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after buying an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after acquiring an additional 2,299 shares during the period. Finally, KBC Group NV grew its holdings in Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after buying an additional 2,340 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 0.8 %

NTLA stock traded down $0.06 during trading on Wednesday, hitting $8.25. The company had a trading volume of 1,711,051 shares, compared to its average volume of 2,366,655. The stock has a market cap of $853.60 million, a PE ratio of -1.52 and a beta of 2.23. The business has a 50-day moving average of $8.83 and a 200-day moving average of $12.01. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.18.

Analyst Ratings Changes

A number of brokerages have issued reports on NTLA. BMO Capital Markets reduced their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research note on Friday, January 10th. Barclays lowered their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Truist Financial decreased their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Finally, Wedbush reaffirmed a "neutral" rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.